New drug cocktail targets Hard-to-Treat liver cancer
NCT ID NCT06811116
First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 2 times
Summary
This study tests two drugs, sapanisertib and cabozantinib, together in people with advanced liver cancer that has a specific genetic change (β-catenin mutation). The goal is to find the safest dose and see if the combination can slow or stop tumor growth. About 92 participants will be enrolled across two phases.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- sapanisertib and cabozantinib
- What this could lead to
- If successful, this combination could offer a new treatment option for people with a specific genetic type of advanced liver cancer that has spread.
- What could go wrong
- This is an early-phase trial with only 92 participants, so results may not apply broadly. The drug combination may cause significant side effects or fail to improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Oregon Health and Science University
RECRUITINGPortland, Oregon, 97239, United States
Contact Email: •••••@•••••
-
UC Irvine Health/Chao Family Comprehensive Cancer Center
RECRUITINGOrange, California, 92868, United States
Contact Email: •••••@•••••
-
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
RECRUITINGIrvine, California, 92612, United States
Contact Email: •••••@•••••
-
UPMC Hillman Cancer Center
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an IDO1 inhibitor boost immunotherapy against liver cancer?
- 3D MRI scan may predict liver cancer treatment success
- New scan could spot hidden cancer left behind after liver surgery
- 3D liver stiffness scan could predict surgery risks
- Immunotherapy drug durvalumab may be safe for liver cancer patients with active hepatitis b
- Immunotherapy-Targeted therapy combo shows promise for advanced liver cancer